| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 30 | 2019 | 958 | 7.480 |
Why?
|
| Mucin-1 | 21 | 2017 | 525 | 5.020 |
Why?
|
| Dendritic Cells | 39 | 2019 | 2594 | 4.540 |
Why?
|
| Multiple Myeloma | 39 | 2019 | 4339 | 4.100 |
Why?
|
| Immunotherapy | 20 | 2019 | 2927 | 2.830 |
Why?
|
| Hematologic Neoplasms | 13 | 2020 | 1404 | 2.280 |
Why?
|
| Immunotherapy, Active | 3 | 2018 | 81 | 1.840 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2019 | 2572 | 1.780 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 25 | 2020 | 4107 | 1.550 |
Why?
|
| Azacitidine | 3 | 2019 | 276 | 1.440 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2018 | 644 | 1.420 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 177 | 1.200 |
Why?
|
| Cell Fusion | 12 | 2012 | 335 | 1.180 |
Why?
|
| Vaccination | 8 | 2018 | 1909 | 0.970 |
Why?
|
| Thalidomide | 5 | 2017 | 862 | 0.930 |
Why?
|
| T-Lymphocytes | 17 | 2018 | 9873 | 0.930 |
Why?
|
| Tumor Microenvironment | 7 | 2019 | 1743 | 0.920 |
Why?
|
| Antigens, Neoplasm | 7 | 2017 | 2055 | 0.910 |
Why?
|
| Immunomodulation | 4 | 2018 | 432 | 0.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2019 | 10051 | 0.790 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2017 | 2661 | 0.780 |
Why?
|
| Stem Cell Transplantation | 9 | 2018 | 1633 | 0.780 |
Why?
|
| Cell Proliferation | 16 | 2017 | 10916 | 0.720 |
Why?
|
| Interleukin-12 | 4 | 2008 | 573 | 0.710 |
Why?
|
| Transplantation, Homologous | 11 | 2018 | 4704 | 0.710 |
Why?
|
| Remission Induction | 9 | 2017 | 2262 | 0.710 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 585 | 0.700 |
Why?
|
| Lymphocyte Activation | 18 | 2018 | 5931 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 13 | 2016 | 9765 | 0.660 |
Why?
|
| Graft vs Host Disease | 11 | 2020 | 2381 | 0.660 |
Why?
|
| Peptides | 6 | 2017 | 4474 | 0.610 |
Why?
|
| Melphalan | 4 | 2014 | 315 | 0.600 |
Why?
|
| Transplantation Conditioning | 5 | 2018 | 1366 | 0.600 |
Why?
|
| Transplantation, Autologous | 12 | 2013 | 1921 | 0.590 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2008 | 967 | 0.580 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 371 | 0.580 |
Why?
|
| Immunity, Cellular | 5 | 2019 | 1666 | 0.570 |
Why?
|
| Immune Tolerance | 4 | 2018 | 2315 | 0.560 |
Why?
|
| Cell Communication | 4 | 2017 | 1599 | 0.540 |
Why?
|
| Dexamethasone | 4 | 2019 | 1773 | 0.520 |
Why?
|
| Molecular Targeted Therapy | 5 | 2018 | 2643 | 0.520 |
Why?
|
| Lymphocyte Transfusion | 2 | 2014 | 237 | 0.510 |
Why?
|
| Recurrence | 11 | 2020 | 7804 | 0.500 |
Why?
|
| Coculture Techniques | 7 | 2017 | 1387 | 0.490 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2019 | 3636 | 0.490 |
Why?
|
| Antigen Presentation | 7 | 2012 | 1334 | 0.480 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 386 | 0.470 |
Why?
|
| Stromal Cells | 1 | 2017 | 1354 | 0.460 |
Why?
|
| Humans | 130 | 2020 | 627531 | 0.460 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2007 | 609 | 0.460 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2017 | 1531 | 0.460 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2015 | 1070 | 0.460 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2012 | 1906 | 0.450 |
Why?
|
| Apoptosis | 10 | 2017 | 10323 | 0.450 |
Why?
|
| Cell Line, Tumor | 17 | 2019 | 16509 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 3 | 2016 | 864 | 0.440 |
Why?
|
| Antigens, CD | 5 | 2016 | 4320 | 0.440 |
Why?
|
| MicroRNAs | 4 | 2018 | 3541 | 0.400 |
Why?
|
| Granzymes | 1 | 2010 | 249 | 0.400 |
Why?
|
| Oxidative Stress | 3 | 2017 | 3219 | 0.390 |
Why?
|
| Kidney Neoplasms | 5 | 2007 | 3507 | 0.380 |
Why?
|
| Cytotoxicity, Immunologic | 7 | 2017 | 1574 | 0.380 |
Why?
|
| Reactive Oxygen Species | 6 | 2017 | 2069 | 0.380 |
Why?
|
| Antineoplastic Agents | 13 | 2017 | 13348 | 0.370 |
Why?
|
| Virus Activation | 3 | 2019 | 325 | 0.370 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1336 | 0.360 |
Why?
|
| Bone Marrow | 1 | 2017 | 2726 | 0.350 |
Why?
|
| Neoplasms | 8 | 2016 | 17034 | 0.350 |
Why?
|
| Interferon-gamma | 6 | 2017 | 3228 | 0.350 |
Why?
|
| Immunologic Factors | 3 | 2018 | 1300 | 0.340 |
Why?
|
| Th17 Cells | 1 | 2012 | 625 | 0.340 |
Why?
|
| Breast Neoplasms | 14 | 2017 | 18451 | 0.340 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 652 | 0.340 |
Why?
|
| Leukemia | 4 | 2016 | 1396 | 0.340 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 1032 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2007 | 230 | 0.330 |
Why?
|
| Killer Cells, Natural | 6 | 2016 | 2116 | 0.330 |
Why?
|
| Immunophenotyping | 10 | 2013 | 1858 | 0.320 |
Why?
|
| Animals | 30 | 2019 | 168063 | 0.310 |
Why?
|
| Oligonucleotides | 1 | 2008 | 584 | 0.310 |
Why?
|
| Flow Cytometry | 10 | 2015 | 6401 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 12 | 2019 | 6788 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2007 | 2518 | 0.290 |
Why?
|
| Anilides | 2 | 2017 | 382 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2018 | 1047 | 0.280 |
Why?
|
| Antigens, CD34 | 5 | 2016 | 697 | 0.280 |
Why?
|
| Boronic Acids | 4 | 2014 | 1022 | 0.270 |
Why?
|
| Th1-Th2 Balance | 2 | 2012 | 36 | 0.260 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 136 | 0.260 |
Why?
|
| Drug Synergism | 6 | 2017 | 1928 | 0.250 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2016 | 300 | 0.250 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2017 | 444 | 0.250 |
Why?
|
| Pyrazines | 4 | 2014 | 1178 | 0.250 |
Why?
|
| Signal Transduction | 6 | 2017 | 23809 | 0.250 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 2042 | 0.250 |
Why?
|
| Immune System | 2 | 2018 | 770 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2018 | 8263 | 0.240 |
Why?
|
| Hodgkin Disease | 3 | 2019 | 1353 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 758 | 0.230 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 3869 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 988 | 0.230 |
Why?
|
| Oncogene Proteins | 2 | 2016 | 764 | 0.220 |
Why?
|
| Down-Regulation | 3 | 2019 | 3298 | 0.220 |
Why?
|
| Mice, SCID | 3 | 2016 | 2824 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2010 | 3029 | 0.220 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 661 | 0.220 |
Why?
|
| Vitamin D | 2 | 2012 | 2764 | 0.210 |
Why?
|
| Cell Differentiation | 10 | 2017 | 11789 | 0.210 |
Why?
|
| Mice, Inbred NOD | 2 | 2015 | 1879 | 0.210 |
Why?
|
| Isoantigens | 2 | 2017 | 587 | 0.210 |
Why?
|
| Lymphocyte Culture Test, Mixed | 6 | 2009 | 666 | 0.200 |
Why?
|
| Cytarabine | 3 | 2019 | 641 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2013 | 3423 | 0.190 |
Why?
|
| Interleukin-2 | 3 | 2016 | 1967 | 0.190 |
Why?
|
| Herpesvirus 6, Human | 1 | 2018 | 95 | 0.190 |
Why?
|
| Oxidation-Reduction | 4 | 2017 | 2355 | 0.190 |
Why?
|
| Middle Aged | 47 | 2020 | 204499 | 0.190 |
Why?
|
| Cross-Priming | 1 | 2017 | 80 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 5383 | 0.190 |
Why?
|
| Blotting, Western | 4 | 2015 | 5999 | 0.190 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2019 | 238 | 0.190 |
Why?
|
| Mice | 18 | 2019 | 79018 | 0.190 |
Why?
|
| Vinblastine | 1 | 2019 | 516 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 3606 | 0.180 |
Why?
|
| Female | 54 | 2020 | 352544 | 0.180 |
Why?
|
| Azepines | 1 | 2019 | 321 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2017 | 4837 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 4 | 2017 | 1473 | 0.180 |
Why?
|
| Perforin | 1 | 2017 | 177 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 4907 | 0.180 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 261 | 0.180 |
Why?
|
| Glutathione | 3 | 2015 | 652 | 0.180 |
Why?
|
| Receptors, CCR7 | 2 | 2008 | 116 | 0.180 |
Why?
|
| Galactosylceramides | 1 | 2017 | 95 | 0.180 |
Why?
|
| Mitoxantrone | 3 | 2017 | 159 | 0.170 |
Why?
|
| JC Virus | 2 | 2014 | 96 | 0.170 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2010 | 438 | 0.170 |
Why?
|
| Aged | 33 | 2020 | 150794 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2017 | 314 | 0.170 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 132 | 0.170 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2015 | 394 | 0.170 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2010 | 93 | 0.170 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1998 | 267 | 0.170 |
Why?
|
| Tretinoin | 1 | 2019 | 535 | 0.170 |
Why?
|
| Adult | 42 | 2020 | 199203 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2001 | 613 | 0.160 |
Why?
|
| Retroviridae | 1 | 2019 | 1007 | 0.160 |
Why?
|
| Ribonuclease III | 1 | 2017 | 247 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2018 | 277 | 0.160 |
Why?
|
| Dacarbazine | 1 | 2019 | 591 | 0.160 |
Why?
|
| Male | 46 | 2020 | 333300 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2016 | 256 | 0.160 |
Why?
|
| Doxorubicin | 4 | 2019 | 2201 | 0.160 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2010 | 187 | 0.160 |
Why?
|
| Etoposide | 3 | 2017 | 630 | 0.150 |
Why?
|
| Hybrid Cells | 2 | 2005 | 505 | 0.150 |
Why?
|
| Pyridines | 2 | 2017 | 2679 | 0.150 |
Why?
|
| Yttrium Radioisotopes | 1 | 2015 | 69 | 0.150 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 473 | 0.150 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2014 | 88 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 3 | 2017 | 2871 | 0.150 |
Why?
|
| Antigen-Presenting Cells | 1 | 2018 | 951 | 0.150 |
Why?
|
| NADP | 1 | 2015 | 250 | 0.150 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 2308 | 0.150 |
Why?
|
| Leukapheresis | 3 | 2003 | 120 | 0.150 |
Why?
|
| Cell Survival | 5 | 2016 | 6433 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 650 | 0.150 |
Why?
|
| Gene Silencing | 3 | 2017 | 1682 | 0.150 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 463 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2018 | 429 | 0.140 |
Why?
|
| Response Elements | 1 | 2016 | 366 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 286 | 0.140 |
Why?
|
| Immunoblotting | 3 | 2014 | 1907 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 574 | 0.140 |
Why?
|
| Immunosuppression | 2 | 2018 | 1515 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2832 | 0.140 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 295 | 0.140 |
Why?
|
| Transplantation | 1 | 2015 | 262 | 0.140 |
Why?
|
| Necrosis | 2 | 2015 | 1656 | 0.140 |
Why?
|
| Fowlpox virus | 1 | 2012 | 20 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 206 | 0.140 |
Why?
|
| Treatment Outcome | 18 | 2018 | 56549 | 0.130 |
Why?
|
| Interleukin-10 | 3 | 2009 | 1186 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 762 | 0.130 |
Why?
|
| Antigens, CD1 | 3 | 2008 | 476 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2012 | 34 | 0.130 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 1828 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2012 | 135 | 0.130 |
Why?
|
| PPAR delta | 1 | 2012 | 87 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 1 | 2018 | 1162 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 791 | 0.130 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 131 | 0.130 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 509 | 0.130 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 266 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1385 | 0.130 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 115 | 0.130 |
Why?
|
| Cells, Cultured | 7 | 2014 | 20919 | 0.130 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 441 | 0.130 |
Why?
|
| Ifosfamide | 2 | 2003 | 230 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 937 | 0.130 |
Why?
|
| Interleukin-4 | 3 | 2014 | 1160 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2012 | 1857 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1083 | 0.120 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8855 | 0.110 |
Why?
|
| Cytokines | 3 | 2017 | 6831 | 0.110 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2010 | 77 | 0.110 |
Why?
|
| Lymphocyte Depletion | 2 | 2006 | 636 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2016 | 1293 | 0.110 |
Why?
|
| Viral Proteins | 1 | 2018 | 1992 | 0.110 |
Why?
|
| Mitogens | 1 | 2010 | 283 | 0.110 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 213 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2019 | 2733 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 1979 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2015 | 13810 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 435 | 0.110 |
Why?
|
| Multiple Organ Failure | 2 | 2010 | 369 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 1740 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 2871 | 0.100 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 995 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2017 | 1690 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 3 | 2017 | 879 | 0.100 |
Why?
|
| Survival Analysis | 7 | 2019 | 10430 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1268 | 0.100 |
Why?
|
| Sirolimus | 1 | 2017 | 1593 | 0.100 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 298 | 0.100 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2005 | 453 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 22505 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 775 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2019 | 3783 | 0.090 |
Why?
|
| Authorship | 1 | 2010 | 237 | 0.090 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 1399 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1056 | 0.090 |
Why?
|
| Isocoumarins | 1 | 2006 | 17 | 0.090 |
Why?
|
| Cell Division | 3 | 2012 | 5037 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2017 | 4383 | 0.090 |
Why?
|
| Cell Separation | 3 | 2016 | 1939 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 2232 | 0.090 |
Why?
|
| Survival Rate | 8 | 2015 | 12802 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2012 | 4132 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 2590 | 0.090 |
Why?
|
| Antimitotic Agents | 1 | 2006 | 34 | 0.090 |
Why?
|
| Filgrastim | 2 | 2007 | 128 | 0.090 |
Why?
|
| Clone Cells | 1 | 2010 | 1755 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 17815 | 0.080 |
Why?
|
| Cell Polarity | 1 | 2010 | 647 | 0.080 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 2058 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2015 | 7012 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2875 | 0.080 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 44 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 994 | 0.080 |
Why?
|
| Lymphocyte Count | 3 | 2016 | 751 | 0.080 |
Why?
|
| Tissue Donors | 3 | 2018 | 1858 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2012 | 1626 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2005 | 123 | 0.080 |
Why?
|
| Lymphoma | 4 | 2017 | 1803 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 7602 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 4086 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 6092 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2014 | 2994 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2010 | 587 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2009 | 642 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 4969 | 0.070 |
Why?
|
| Antibody Formation | 2 | 2005 | 1347 | 0.070 |
Why?
|
| Bone Marrow Cells | 3 | 2004 | 2697 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2018 | 3060 | 0.070 |
Why?
|
| Disclosure | 1 | 2010 | 721 | 0.070 |
Why?
|
| Young Adult | 11 | 2019 | 50739 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2008 | 1244 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2015 | 20360 | 0.070 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1391 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 7727 | 0.070 |
Why?
|
| Gene Expression | 1 | 2017 | 8170 | 0.070 |
Why?
|
| Glucocorticoids | 4 | 2018 | 1992 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2008 | 1022 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6771 | 0.060 |
Why?
|
| Sterilization | 1 | 2003 | 122 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 3096 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2012 | 3644 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 678 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 900 | 0.060 |
Why?
|
| Pancreatitis | 1 | 2007 | 1027 | 0.060 |
Why?
|
| Drug Administration Schedule | 5 | 2013 | 5149 | 0.060 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 55853 | 0.060 |
Why?
|
| CD4-CD8 Ratio | 1 | 2000 | 112 | 0.060 |
Why?
|
| Phytohemagglutinins | 1 | 2000 | 212 | 0.060 |
Why?
|
| K562 Cells | 3 | 2010 | 653 | 0.060 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 406 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 8250 | 0.060 |
Why?
|
| Mitosis | 1 | 2006 | 1291 | 0.060 |
Why?
|
| Idarubicin | 1 | 2019 | 63 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2011 | 2083 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2002 | 592 | 0.050 |
Why?
|
| Antibodies | 1 | 2008 | 2385 | 0.050 |
Why?
|
| Transcription Factors | 2 | 2012 | 11991 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 4666 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 6751 | 0.050 |
Why?
|
| Chronic Disease | 4 | 2018 | 8531 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2017 | 1215 | 0.050 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2000 | 545 | 0.050 |
Why?
|
| U937 Cells | 1 | 2019 | 271 | 0.050 |
Why?
|
| Foscarnet | 1 | 2018 | 40 | 0.050 |
Why?
|
| Prednisone | 2 | 2018 | 1522 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1386 | 0.050 |
Why?
|
| Skin Tests | 1 | 2000 | 637 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2001 | 575 | 0.050 |
Why?
|
| Bacterial Vaccines | 1 | 2001 | 431 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 2827 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 10118 | 0.050 |
Why?
|
| Chimerism | 1 | 2018 | 134 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 1999 | 236 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 8048 | 0.050 |
Why?
|
| Contrast Media | 1 | 2011 | 5196 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2020 | 2588 | 0.050 |
Why?
|
| Heartburn | 1 | 2017 | 52 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2000 | 883 | 0.040 |
Why?
|
| Quality of Life | 1 | 2016 | 9060 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 36 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2016 | 104 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 1959 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2016 | 114 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 27125 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2003 | 3063 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2001 | 1025 | 0.040 |
Why?
|
| Phenotype | 3 | 2011 | 14970 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2001 | 522 | 0.040 |
Why?
|
| Mediastinum | 1 | 2017 | 239 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2017 | 187 | 0.040 |
Why?
|
| Models, Biological | 2 | 2012 | 10316 | 0.040 |
Why?
|
| Immunity | 1 | 2000 | 647 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 272 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 311 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2016 | 133 | 0.040 |
Why?
|
| Fatigue | 2 | 2013 | 1168 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2001 | 850 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 293 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 7111 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 3992 | 0.040 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 92 | 0.040 |
Why?
|
| Protein Binding | 1 | 2008 | 10041 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 623 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 9938 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 9807 | 0.040 |
Why?
|
| Antigens, CD1d | 2 | 2008 | 217 | 0.040 |
Why?
|
| Retreatment | 1 | 2016 | 589 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2019 | 35693 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 1371 | 0.040 |
Why?
|
| Computational Biology | 2 | 2017 | 3309 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 11652 | 0.040 |
Why?
|
| Neutrophils | 2 | 2017 | 3631 | 0.040 |
Why?
|
| Acute Disease | 2 | 2017 | 7100 | 0.040 |
Why?
|
| Chile | 1 | 2013 | 157 | 0.040 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 38061 | 0.040 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 297 | 0.030 |
Why?
|
| Pulmonary Heart Disease | 1 | 1993 | 49 | 0.030 |
Why?
|
| Carcinoma | 2 | 2002 | 2337 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2016 | 548 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 14927 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 809 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 397 | 0.030 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 415 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 419 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 147 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 12246 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2010 | 4086 | 0.030 |
Why?
|
| Israel | 1 | 2013 | 594 | 0.030 |
Why?
|
| Telomerase | 1 | 2016 | 697 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 41572 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 133 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 1113 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 19754 | 0.030 |
Why?
|
| Cadherins | 1 | 2016 | 947 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 807 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2011 | 1588 | 0.030 |
Why?
|
| Cell Culture Techniques | 3 | 2004 | 1766 | 0.030 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 39 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 1090 | 0.030 |
Why?
|
| Myelopoiesis | 1 | 2010 | 135 | 0.030 |
Why?
|
| Paclitaxel | 3 | 2002 | 1565 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2014 | 1016 | 0.030 |
Why?
|
| Observation | 1 | 2011 | 318 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 26794 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2582 | 0.030 |
Why?
|
| United States | 2 | 2013 | 59314 | 0.030 |
Why?
|
| Viral Load | 1 | 2018 | 2930 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 1025 | 0.030 |
Why?
|
| Neutropenia | 1 | 2013 | 803 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2011 | 302 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2010 | 161 | 0.030 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2009 | 212 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 132 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2017 | 56996 | 0.020 |
Why?
|
| Arsenicals | 1 | 2008 | 131 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 1072 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 688 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 351 | 0.020 |
Why?
|
| India | 1 | 2013 | 1929 | 0.020 |
Why?
|
| Biopolymers | 1 | 2009 | 229 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1665 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2001 | 4697 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2016 | 2398 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 471 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1993 | 801 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 2087 | 0.020 |
Why?
|
| ADP Ribose Transferases | 1 | 1986 | 96 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2006 | 71 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 656 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 4054 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 863 | 0.020 |
Why?
|
| Exotoxins | 1 | 1986 | 130 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 1026 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1636 | 0.020 |
Why?
|
| Pneumonia | 1 | 2016 | 1828 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3808 | 0.020 |
Why?
|
| Oxides | 1 | 2008 | 445 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 4365 | 0.020 |
Why?
|
| HLA-DR Antigens | 2 | 1999 | 709 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2014 | 2824 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 4512 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2017 | 2722 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2011 | 1278 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 1011 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 20059 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 850 | 0.020 |
Why?
|
| Thiazoles | 1 | 2012 | 1501 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 807 | 0.020 |
Why?
|
| Adolescent | 6 | 2012 | 79142 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 2132 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1997 | 4172 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 4526 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 6291 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 868 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 2178 | 0.020 |
Why?
|
| Vaccines, Conjugate | 1 | 2005 | 324 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 790 | 0.020 |
Why?
|
| Pain | 2 | 2010 | 4055 | 0.020 |
Why?
|
| Thiotepa | 1 | 2002 | 77 | 0.020 |
Why?
|
| Catheterization | 2 | 2003 | 1528 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 4406 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 72 | 0.020 |
Why?
|
| Virulence Factors | 1 | 1986 | 506 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 10674 | 0.020 |
Why?
|
| Physician's Role | 1 | 2010 | 1004 | 0.020 |
Why?
|
| Life Tables | 1 | 2002 | 386 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 2002 | 173 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2010 | 38643 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 3650 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1764 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2002 | 206 | 0.010 |
Why?
|
| Risk Factors | 3 | 2019 | 64487 | 0.010 |
Why?
|
| Macrophages | 1 | 1996 | 5550 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 315 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 2572 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1998 | 0.010 |
Why?
|
| Bilirubin | 1 | 2002 | 375 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1986 | 895 | 0.010 |
Why?
|
| Ascites | 1 | 2002 | 323 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2020 | 44747 | 0.010 |
Why?
|
| Immunization | 1 | 2005 | 1218 | 0.010 |
Why?
|
| Prevalence | 1 | 2017 | 13874 | 0.010 |
Why?
|
| Microtubules | 1 | 2006 | 1171 | 0.010 |
Why?
|
| Neoplasm Metastasis | 2 | 2002 | 5168 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 10717 | 0.010 |
Why?
|
| Cell Line | 2 | 2008 | 17253 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 536 | 0.010 |
Why?
|
| Mitochondria | 1 | |